---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-121068"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:22:27.127748+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics Q3 net loss $26.4M; FDA lifts partial clinical hold on zorevunersen; STK-002 Phase 1 delayed

## Summary
- Cash, equivalents, and marketable securities $269.2M as of Sep 30, 2024.
- Net loss Q3 2024 $26.4M ($0.47/shr) vs $24.5M ($0.55/shr) Q3 2023.
- Revenue from Acadia collaboration $4.9M in Q3 2024 vs $3.3M in Q3 2023.
- FDA removed partial clinical hold on zorevunersen; plans to provide Phase 3 data and regulatory update by year-end.
- Phase 1 study of STK-002 (ADOA) delayed to focus on zorevunersen.

## SEC filing metadata
- accession: 0000950170-24-121068
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000095017024121068/0000950170-24-121068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000095017024121068/stok-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-121068
- JSON: https://secwatch.observer/filing/0000950170-24-121068.json
- Plain text: https://secwatch.observer/filing/0000950170-24-121068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.